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An increase in the number of identified therapeutic cancer targets achieved through recent biomedical research has resulted in the
generation of a large number of molecules that need to be tested further. Current development of (anticancer) drugs is a rather
inefficient process that for an average new molecule takes around 10–15 years. It is also a challenging process as it is associated with
high costs and a low rate of approval. It is known that less than 10% of new molecular entities entering clinical Phase I testing progress
beyond the investigational programme and reach the market; this probability is even lower for anticancer agents. In 2003, the US
Food and Drug Administration (US FDA) declared the urgent need for new toolkits to improve the critical development path that
leads from scientific discovery to the patient. In this scenario, Phase 0 (zero) trials should allow an early evaluation in humans of
pharmacokinetic and pharmacodynamic profiles of test compounds through administration of sub-pharmacological doses and for a
short time period to a low number of humans. Typically, Phase 0 studies have no therapeutic or diagnostic intent. Owing to the low
doses administered and the low risk of toxicity, shorter preclinical packages to support these studies are required. Phase 0 trials have
been proposed to help in making an early selection of promising candidates for further evaluation in Phase I–III trials, providing a
potentially useful instrument for drug discovery, particularly in the field of oncology. Phase 0 studies are expected to reduce costs of
drug development, and to limit the preclinical in vitro and in vivo testing and the time period of drug development. However, there are
also concerns about the utility and feasibility of Phase 0 studies. In January 2006, guidelines on exploratory investigational new drug
studies in humans have been published by the US FDA, and currently a Phase 0 programme is ongoing at the National Cancer
Institute to evaluate the impact (feasibility and utility) of Phase 0 studies on drug development. In Europe, a Position Paper produced
by the Evaluation of Medicinal Products (EMEA) in 2004 raised the possibility of a reduced preclinical safety package to support early
microdose clinical studies, and, as announced by a recent Concept Paper on medicinal products published by the committee for
medicinal products for human use of the EMEA, EMEA’s guidelines on Phase 0 studies are expected shortly. The true impact of Phase
0 studies on the drug development process as well as on the safety needs to be carefully explored.
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Drug development is a long, complex and expensive process. The
conventional sequence of processes involved in drug development
comprises a preclinical phase and three clinical phases, Phases 1, 2
and 3. Currently, the typical development for investigational new
drugs takes between 10 and 15 years and is associated with high
costs and low rate of approval (DiMasi et al, 2003). Owing to the
fast progress in biomedical and pharmaceutical research, the
number of new molecular entities starting the development
process has increased significantly since about 1990; however,
the rate of approval for marketing is declining: in 2005, only 20
new drugs were approved by the US Food and Drug Administra-
tion (US FDA), compared with 36 in 2004 and 53 in 1996
(Twombly, 2006). It has been estimated that currently a novel
compound entering clinical Phase I testing has only an 8% chance
of reaching the market, and the probability is even lower for
an anticancer drug (Food and Drug Administration, 2006,
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf; Kola
and Landis, 2004). This low success rate has been ascribed to the
high number of new molecular entities with diverse mechanisms of
action (MOA) to be tested for activity and efficacy combined with
the lack of predictive preclinical models and inadequate and
complex clinical trial designs. Overall 75% of the costs of drug
development is associated with failures mainly in the early stages
of development (Goodall, 2004). Often the toxicity is severe and
poorly predictable. Furthermore, 40% of exits from Phase I trials
are caused by inappropriate pharmacokinetics of the test
compound (DiMasi, 2001, 2002); Wang and Urban, 2004). Several
investigational new drugs fail in clinical testing because they do
not behave pharmacologically as predicted in animal studies.
Consequently, there is a need for additional methods to evaluate
potential new drugs and to optimise existing development
strategies. This is particularly true for the field of oncology where
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involved in malignant cellular transformation has led to major
changes in therapeutic approaches. Anticancer drugs able to
inhibit specific targets responsible for malignant cellular transfor-
mation (e.g. genes, proteins, growth factors and receptors) and
involved in specific pathways (e.g. angiogenesis, apoptosis, signal
transduction, metastasis, drug resistance, etc.) have been dis-
covered. Moreover, the application of combinatorial chemistry
further increased the number of potential therapeutic agents
(Leonard et al, 2001). In contrast with the traditional nonspecific
cytotoxic antiproliferative agents, which often have a small
therapeutic window, steep dose–toxicity curve and an efficacy
assumed to be somehow related to toxicity, molecularly targeted
agents usually show less toxicity, a wider therapeutic window and
an efficacy more related to growth inhibition than to tumour
shrinkage (Fox et al, 2002; Workman et al, 2006). Clearly,
strategies used for the development of cytotoxic agents may not
be suitable for molecularly targeted agents.
Consequently, new tools and strategies to make the drug
development process faster and more efficient are being explored.
In view of this, Phase 0 clinical studies have been proposed to
modernise and optimise the clinical trial process (Kummar et al,
2007).
PHASE 0 CLINICAL TRIALS
Phase 0 trials are clinical studies conducted early in Phase I, before
the traditional dose escalation, safety and tolerance studies. These
first-in-man trials should involve a very limited number of normal
volunteers or patients, exposed to a novel compound at a reduced
dose compared to starting doses in Phase I and for a short time
period. Phase 0 clinical trials have no therapeutic or diagnostic
purpose for the volunteer; in principle, they should allow
researchers to quickly establish whether a novel compound has
appropriate pharmacokinetic and pharmacodynamic profiles in
humans. Phase 0 trials will not replace the traditional dose
escalation, safety and tolerance studies and they will not indicate
whether a candidate drug has a positive impact on the targeted
disease. However, owing to the low doses administered, the limited
number of humans treated and the reduced risk of toxicity, the
Phase 0 strategy would require fewer preclinical in vitro and in
vivo studies than a typical Phase I trial and a reduced amount of
the experimental drug. Potentially, Phase 0 clinical studies could
help in eliminating candidate drugs before they reach Phase I
testing, thus reducing costs and time and improving the efficiency
of drug development.
EVALUATION OF MEDICINAL PRODUCTS GUIDANCE
In 2003, the European Agency for the Evaluation of Medicinal
Products (EMEA) published a concept note followed by a Position
Paper on the nonclinical safety studies needed to support human
clinical trials with a single dose of a pharmacologically active
compound using microdose techniques (CPMP/SWP/2599/02/
Rev1, http://www.emea.europa.eu/pdfs/human/swp/259902en.pdf).
The Paper raises the possibility of a reduced preclinical safety
package for sub-pharmacological (micro)dose clinical studies. The
proposals of the EMEA are a major step forward in the recognition
of the potential utility of microdose Phase 0 trials in improving the
drug development process. As intended by EMEA, the aim of
microdose studies is to evaluate human plasma pharmacokinetics
and/or distribution properties or receptor selectivity profile of new
drug candidates as early as possible in the preclinical stage of
development. Theoretically, microdose trials should allow an early
selection between promising and inappropriate molecules for
further development.
In microdose trials, sub-pharmacological single doses (in the
low microgram range) of test drug are administered to a small
number of humans (healthy volunteers or patients). Ultrasensitive
analytical methods (e.g. positron emission tomography (PET),
accelerated mass spectrometry (AMS)) are needed to assess human
exposure and drug distribution to estimate the pharmacokinetics
of higher, clinically relevant doses, assuming linear pharmaco-
kinetics.
The Paper defines a microdose as less than 1/100th of the dose of
the test substance calculated from in vitro and animal models to
yield a pharmacological effect, with a maximum dose of p100mg.
Microdose clinical trials may be conducted with a single test
substance or with several closely related molecules to choose the
more promising candidate or formulation.
As indicated in the Position Paper, an extended single-dose
toxicity study in only one appropriate mammalian species with a
control group is considered sufficient to support a microdose
human trial if justified by comparative in vitro data. A sufficient
number of animals to guarantee reliable interpretation of the
results should be treated and two routes of administration (the
intravenous and the clinically intended, when different from
intravenous) are recommended. Animals should be observed for
14 days with an interim necropsy on day 2. Haematologic, clinical
chemistry and histopathologic data as well as information
regarding other relevant organ systems should be collected after
2 and 14 days at minimum. Gross necropsy of all animals is
recommended. Notably, as indicated in the Position Paper, a safety
factor of 1000 should be used to calculate the limit dose from
animals to humans. In vitro genotoxicity tests are required,
although under certain circumstances they can be limited.
Moreover, all preclinical safety studies should be performed in
accordance with the principles of Good Laboratory Practice.
EMEA’s guidelines on Phase 0 trials are currently being
prepared. In March 2006, the committee for medicinal products
for human use (CHMP) of the EMEA published a Concept Paper
about the development of a CHMP guideline on the nonclinical
requirements to support early Phase I clinical trials with new
pharmaceutical compounds (CHMP/SWP/91850/2006, http://
www.emea.europa.eu/pdfs/human/swp/9185006en.pdf). A revised
toxicology package designed to support Phase 0 trials without
compromising human safety has already been discussed by the
CHMP Safety Working Party (SWP) and the preparation of the
guideline is ongoing. As anticipated in the Concept Paper, the
guidance is intended ‘to facilitate a directed exploration of the
physiology, pharmacology and/or pharmacokinetics of one or
more candidate pharmaceutical products in humans’ in order ‘to
optimise the selection of safer, more effective therapeutics for
further development and ultimately make them available to
patients sooner’. The guidance will describe early Phase I
exploratory (Phase 0) approaches. These studies should evaluate
pharmacokinetic and/or pharmacodynamic properties of the test
molecule, possibly using a sensitive biomarker of activity. A dose–
exposure relationship in humans could be obtained too. The
guidelines will standardise and facilitate the requirements for
Phase 0 trials and should allow flexibility of approaches.
Phase 0 clinical studies were not mentioned in the revised
guidelines on the evaluation of anticancer medicinal products in
humans published by the CHMP in December 2005 (CPMP/EWP/
205/95/Rev.3/Corr.2, http://www.emea.eu.int/pdfs/human/ewp/
020595en.pdf), although it has been proposed that one of the
most interesting fields of application of Phase 0 trials could be the
discovery/development process of new molecularly targeted anti-
cancer compounds. However, current EMEA’s guidelines on the
clinical investigation of anticancer agents provide different
opportunities for the evaluation of cytotoxic and non-cytotoxic
anticancer compounds. These guidelines allow large flexibility in
designing Phase I/II exploratory trials, provide opportunities to
perform early trials in healthy volunteers besides cancer patients,
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effective dose) and encourage the evaluation of pharmacodynamic
parameters previously not explored (e.g. biochemical and im-
munological parameters, functional imaging, proteomics, etc.).
Therefore, we believe that most (if not all) issues explored by Phase
0 trials could already be addressed based on the outlined EMEA
guidance and by an adequate Phase I study strategy, but official
guidelines on Phase 0 studies could standardise and facilitate this
new strategy in the evaluation of novel anticancer drugs.
US FOOD AND DRUG ADMINISTRATION GUIDANCE
In the Critical Path Report published on March 2004, the US FDA
denounced the ‘slowdown, instead of the expected acceleration, in
innovative medical therapies reaching patients’ owing to a medical
product development path ‘increasingly challenging, inefficient
and costly’. US Food and Drug Administration declared the urgent
need for new toolkits to modernise the critical development path
that leads from scientific discovery to the patients. The aim was to
improve the medical product development process to speed up
‘robust development pathways that are efficient and predictable
and result in products that are safe, effective and sooner available
to patients’ (Food and Drug Administration, 2006, http://
www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf).
Following these concepts in April 2004, US FDA published a
draft guidance regulating early human screening studies, and in
January 2006 new industry guidelines for early exploratory drug
studies in humans have been issued (http://www.fda.gov/cder/
guidance/7086fnl.htm). The aim of the guidance, developed by the
Center for Drug Evaluation and Research (CDER) (2006), was to
‘clarify what preclinical and clinical approaches, as well as
chemistry, manufacturing and controls information, should be
considered when planning exploratory studies in humans, includ-
ing studies of closely related drugs or therapeutic biological
products, under an investigational new drug application’. The
guidelines defined also the characteristics and the aim of
investigational new drug studies. In brief, they are defined as
clinical trials conducted early in Phase I of clinical development in
a very limited number of patients or healthy volunteers. The
duration of dosing of the candidate compound should be limited
(e.g. 7 days). These studies should not have any therapeutic or
diagnostic purpose. The aim of Phase 0 studies is to explore
pharmacokinetic and pharmacodynamic profiles of novel com-
pounds in humans, to confirm in humans a mechanism of action
(MOA) previously observed in experimental systems and to help in
the early selection of the most promising lead product from a
group of candidates interacting with a particular therapeutic
target.
Interestingly, US FDA’s guidance does not issue new regulations,
but is an interpretation of existing recommendations on drug
development. In particular, knowing that limited early Phase I
studies were often supported by a more extensive preclinical
database than was required by the regulations, the guidance
addresses not only chemistry and manufacturing, but also the level
and the type of preclinical safety testing recommended for an
exploratory investigational new drug application.
The guidance describes in detail also three types of Phase 0
studies: clinical studies of pharmacokinetics or imaging (also
noted as microdose studies), clinical trials to study pharmacolo-
gically relevant doses and clinical studies of MOAs related to
efficacy.
Microdose or imaging studies are designed to evaluate pharma-
cokinetics, metabolism or imaging distribution of compounds.
Analogous to the microdose trials described in the EMEA Position
Paper, after the administration of very low doses of the novel
molecular entities to few humans, very sensitive assay methods
(e.g. PET, AMS) are needed to explore human pharmacokinetics
and tissue distribution. The concept of microdose defined by the
US FDA is analogous to the EMEA: one-hundredth of the proposed
pharmacological dose from in vivo and/or in vitro data with a
maximum dose of p100mg (or p30nanomol for protein
products). Considering that such low (sub-pharmacological) doses
are not expected to have clinically significant toxic potential,
reduced preclinical safety packages, bulk drug synthesis (CMC-
chemistry, manufacturing and control requirements) and easier
formulation are justified in some cases.
Analogous to the EMEA recommendations, extended single-
dose toxicity studies in both genders of a single mammalian
species to establish a dose inducing a minimal toxic effect or a
safety margin are considered sufficient to support a human
microdose study if justified by in vitro data. In contrast to the
EMEA indications, routine genetic toxicology and safety pharma-
cology tests are not required.
As intended by the US FDA, microdose studies should be
utilised in oncology, primarily for imaging end points. However,
the Phase 0 guidance provides the opportunity to assess
pharmacokinetic and pharmacodynamic parameters as well.
Clinical trials to study pharmacologically relevant doses are the
second type of Phase 0 studies described in the US FDA’s guidance.
They are aimed to explore pharmacologic effects of a test molecule.
These Phase 0 studies have no therapeutic or diagnostic purpose
and are not meant to evaluate the maximally tolerated dose. The
support of a preclinical safety package is more extensive than that
of microdose studies, but still less than is required for traditional
Phase I investigational new drug studies. Phase 0 studies to
investigate pharmacologically active doses may include repeat dose
clinical trials lasting up to 7 days.
Other Phase 0 trials described in the US FDA’s guidance are
clinical studies of MOAs related to efficacy. They are designed to
evaluate the pharmacodynamic effect of a new drug that is
expected to be correlated with its clinical activity. Typically, these
Phase 0 trials present biomolecular end points, such as the rate of
an enzyme inhibition or the degree of saturation of a receptor.
These clinical studies of MOAs related to efficacy have been
proposed as particularly useful in the oncology field for the
evaluation of molecularly targeted anticancer agents. Indeed,
according to the guidance, based on careful preclinical studies
and appropriate assay development, a single dose of a targeted
agent can be delivered with minimal risk (since such agents have
been developed for chronic administration) at a level that has the
potential to have a pharmacodynamic effect in tumour tissues in
patients. This is expected to speed up drug development timelines
by early evaluation of target effects and the usefulness of the assay
systems for such targets.
To explore feasibility and utility of the Phase 0 strategy, after the
publication of the US FDA guidelines, the National Cancer
Institute (NCI, 2006) started the NCI Phase 0 programme and
currently a Phase 0 pharmacokinetic and pharmacodynamic study
of ABT-888, an inhibitor of poly(ADP-ribose) polymerase (PARP),
in patients with refractory solid tumours and lymphoid
malignancies, is ongoing (http://clinicaltrials.gov/ct/show/
NCT00347633). This non-therapeutic study is designed to explore
the pharmacokinetics, pharmacodynamics, side effects and safety
of ABT-888. The programme will evaluate the real impact of
the early-in-humans investigational new drug studies on drug
development.
POTENTIAL ADVANTAGES AND DISADVANTAGES
OF PHASE 0 STUDIES
The Phase 0 trials were designed to improve the drug development
pathway.
Phase 0 trials may shorten time periods to first-in-human
studies through an earlier evaluation of human pharmacology of a
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to explore pharmacokinetic and pharmacodynamic profiles of
candidate drugs in humans (such as bioavailability, metabolism,
tissue distribution), thus potentially helping in the early selection
of promising compounds for further development before tradi-
tional Phase I trials. Indeed, one of the major limitations in
anticancer drug development is the poor correlation between
preclinical and clinical pharmacokinetics and pharmacodynamics.
The early evaluation in humans of the candidate drug could
potentially help in accelerating the selection of promising
compounds, thus increasing the efficiency of the drug develop-
ment process. The bioreductive agent EO9 was developed in Phase
I; however, its pharmacokinetics in plasma showed extensive and
rapid degradation to inactive metabolites, making the drug
unsuitable for intravenous application (Schellens et al, 1994).
The time-consuming and costly Phase I study could have been
prevented if a Phase 0 study would have been performed. In
addition, inactive treatment of patients who took part in that study
could have been more limited.
Considering the reduced risk of human toxicity owing to the low
dose of the test drug administered and the short time period of
drug exposure in Phase 0 trials, the preclinical safety packages,
animal use, amount of test drug, development time and costs will
be reduced.
However, Phase 0 trials may get drugs faster into the clinic, but
there are still concerns whether they can significantly shorten the
drug development process, as they will not replace the traditional
dose escalation, safety, tolerance and efficacy studies.
Other limitations relate to the lack of therapeutic intent of
Phase 0 trials. The lack of therapeutic benefit is justified by the
risk for the patient that is clearly less in a single-dose Phase 0
trial than in a standard dose-escalation Phase I study. However,
in Phase I trials, although developed without therapeutic intent,
there is on average a low response rate of about 5% (Von Hoff
and Turner, 1991), whereas in Phase 0 trials no therapeutic gain
can be expected. Therefore, besides the ethical issue, the
motivation of patients to participate in a Phase 0 trial may
significantly affect the success rate of these trials. Similar to several
Phase I studies, in Phase 0 trials, serial tumour biopsies may need
to be obtained or other invasive procedures may be necessary.
Invasive procedures can be justified by the fact that more effort
should be undertaken to develop decisive pharmacodynamic
assays. However, it is difficult to envisage that an end-stage
patient will consider to undergo multiple hospital admissions,
multiple pharmacokinetic samplings and serial tumour biopsies
without any potential benefit. If safe enough, the evaluation of the
pharmacokinetics of a drug candidate can be conducted in healthy
volunteers; however, pharmacodynamic measurements in tumour
tissues and studies with cytotoxic agents have to be evaluated in
patients.
Furthermore, participation in a Phase 0 trial might delay or
exclude the patient from other clinical trials that may have some,
although little, therapeutic intent. Although the total duration of a
patient’s participation in a Phase 0 trial is short and is expected to
last no longer than 1 week, not only the preparation for a
subsequent clinical study may be delayed but also a wash-out
period may need to be taken into consideration. These issues may
significantly impair patient recruitment, thus influencing the
feasibility of Phase 0 trials.
There are other limitations regarding microdose studies. The US
FDA guidance states that microdose studies should be utilised in
oncology, primarily for imaging end points. However, as intended
by the EMEA’s Position Paper, microdose studies could be used to
evaluate human plasma pharmacokinetics and/or distribution
properties or the receptor selectivity profile of new drug
candidates. In this case, an important question is whether there
is a good correlation between the pharmacokinetics of a microdose
and of a therapeutically relevant dose. In a study conducted by the
Consortium for Resourcing and Evaluating AMS Microdosing, five
drugs for which it was difficult to predict human pharmacokinetics
were administered to subjects at a microdose and at a therapeutic
dose level. Of the five drugs evaluated, microdose measurements
predicted the pharmacokinetics of three compounds well when
administered at therapeutic levels and gave important metabolism
data for one drug. An approximately 70% correspondence between
the pharmacokinetics of a microdose and of a pharmacologically
relevant dose was found. Microdosing appears to be appropriate
for compounds (e.g. small organic molecules, peptide and protein
therapeutics) with linear pharmacokinetics, small molecules with
short half-lives or compounds that are metabolised and that have a
rapid dissociation of binding to their target. In contrast,
microdosing was not predictive for molecules with nonlinear
pharmacokinetics and/or with high-affinity binding to their targets
(Lappin and Garner, 2003; Garner, 2005; Wilding and Bell, 2005;
Singh, 2006; Lappin et al, 2006).
Another important concern is that for predicting anticancer
activity, there are few validated biomarkers. Pharmacological,
biological or imaging measurements at very low exposure levels
are required, but unfortunately few reliable and validated assays
are currently available even for most approved targeted cancer
drugs. Moreover, along with novel therapeutic targets, more potent
anticancer molecules have been discovered recently. This implies
the use of lower doses than of traditional anticancer agents, thus
potentially creating significant problems regarding the bioanaly-
tical techniques. Indeed, for microdose studies, very sensitive
analytical methods (such as PET or AMS) are needed, and
currently these techniques are not routinely available (Gupta et al,
2002). This factor may further limit the application of Phase 0
microdose studies.
CONCLUSIONS AND PERSPECTIVES
In its recent guideline, the US FDA gave clear prerequisites,
principles and instructions for the execution of Phase 0 trials. Also
the recently modified EMEA note for guidance on the development
of anticancer medicinal products, supported by other EMEA
guidelines, gives clear instructions about the prerequisites and
execution of early clinical trials with anticancer agents. The EMEA
currently prepares a guideline for Phase 0 trials that will
supplement the existing guidelines.
Phase 0 trials are expected to improve the efficiency of
(anticancer) drug development and to reduce costs. The rate of
failure of drugs entering Phase I clinical trials should come down
as a proof that Phase 0 trials are beneficial. Furthermore, Phase 0
trials should contribute to fast-track and safe drug development.
Future experience should tell whether these expectations would be
fulfilled. Therefore, critical evaluation of Phase 0 trials is necessary,
especially in terms of safety. One should prevent that Phase 0 trials
will be used to circumvent proper safety assessment in the
preclinic as well as proper assessment of proof of concept of
antitumour activity of a clinical candidate drug before first-in-man
studies are being performed. Furthermore, it should be critically
monitored whether Phase 0 trials contribute to faster drug
development without putting patients at unacceptable risks.
Execution of Phase 0 trials may be hampered by ethical reasons
as well as by the willingness of patients to take part in these trials
that will have no therapeutic benefit to them.
Despite the opportunities provided by Phase 0 trials, new animal
models with humanised biotransformation systems and drug
transporters, and animals bearing genetically modified tumours
better reflecting human tumour biology and drug disposition (the
so-called ‘mouse clinic’), could significantly improve the drug
development process. By using these models, it is expected that
more efficient, faster and less costly drug development is achieved,
especially by better preclinical selection of clinical candidates
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by selection of clinical candidates with better pharmacological
profiles and by better definition of the target population of patients
during clinical development.
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